(firstQuint)Efficacy and Safety of Humira in Patients With Psoriatic Arthritis in Normal Medical Practice.

 Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years.

 Patients receive adalimumab 40 mg every other week (eow), per its label.

 Efficacy and safety parameters are measured routinely at baseline and after 3, 6, 9, 12, 18 and 24 months.

.

 Efficacy and Safety of Humira in Patients With Psoriatic Arthritis in Normal Medical Practice@highlight

This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.

